Niagara Falls

Researchers are evaluating a program that integrates Community Health Workers (CHWs) into community pharmacies in under-resourced areas of Western New York to address social needs. This study uses a quasi-experimental design to compare outcomes between patients who receive social needs screenings and referrals and those who do not within the same healthcare system. In this study, community pharmacies distribute social needs screening surveys to patients and refer those with identified needs to local community-based organizations. Patients are grouped into those who receive no intervention and those who receive screenings and referrals. The study focuses on pharmacies enrolled in the Community Pharmacy Enhanced Services Network - NY or associated with Tops Pharmacies in Erie County. Participants will be adults aged 18 years or older who visit participating pharmacies. Researchers will monitor the effectiveness of the social needs screening and referral program over 12 months, including cost analysis. The study involves collecting information through surveys and tracking referrals to community resources, with ongoing evaluation of outcomes related to social needs status.

Researchers are evaluating the efficacy and safety of vormatrigine in adults with focal seizures. This Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial aims to compare different doses of vormatrigine with a placebo in adults who are currently taking one to three antiseizure medications (ASMs). The study focuses on participants diagnosed with focal onset epilepsy and excludes those with progressive causes of epilepsy or other complicating conditions. Participants will be randomly assigned at the start of the study to receive one of three doses of vormatrigine (40 mg, 30 mg, or 20 mg) or a placebo, taken once daily by mouth for 12 weeks. The trial includes multiple study arms to compare these dose groups directly against placebo under blinded conditions to ensure unbiased results. During the 12-week treatment period, participants will be monitored for their focal seizure frequency using seizure diaries and other assessments. Safety and tolerability will also be evaluated throughout the study. The main outcome will measure the change in seizure frequency compared to placebo during the 12 weeks. Participants will attend scheduled study visits for ongoing assessments, including adherence, safety monitoring, and seizure tracking. The study is expected to conclude by May 2027.

Researchers are evaluating olpasiran, a drug given by injection, to see if it can reduce the risk of first major heart-related events like coronary heart disease death, heart attacks, or urgent coronary procedures in people with high levels of lipoprotein(a) and risk factors for cardiovascular disease. This is a phase 3, double-blind, randomized, placebo-controlled study aiming to improve prevention strategies for cardiovascular disease. Participants will be randomly assigned to receive either subcutaneous injections of olpasiran or a placebo. The study compares these two groups over a period of up to approximately 6.2 years to assess their impact on major cardiovascular events. The treatment is given by injection under the skin, with one group receiving the active drug and the other receiving a placebo injection. During the study, participants will be monitored regularly for heart-related events including death from coronary heart disease, heart attacks, strokes, and urgent coronary procedures. Blood levels of lipoprotein(a) and olpasiran will be measured at baseline and at week 48. The study will also track any treatment-emergent side effects and overall health outcomes over the course of up to 6.2 years, giving a comprehensive view of the drug’s potential effects and safety.